Compare BioNano Genomics Inc (BNGO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Schlumberger NV — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Schlumberger NV trades at $47.36 (market cap $71.08B). The key difference: Schlumberger NV is far larger — about 5384.8× BioNano Genomics Inc's market cap, and Schlumberger NV pays a 2.48% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SLB | |
|---|---|---|
Market Cap | $13.20M | $71.08B |
Sector | Health | Energy |
52-Week High | $4.92 | $58.01 |
52-Week Low | $1.09 | $31.72 |
Enterprise Value | $15.81M | $79.30B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SLB trades at $47.36, down 0.84% on the day, with a neutral technical signal. The company reported revenue of $35.71 billion in 2025, with a net income margin of 9.26% and a P/E ratio of 20.86. Recent news includes a major EPC contract win for the Baleine Phase 3 development and a strategic alliance with Liberty Energy for data center infrastructure, highlighting diversification efforts.
The outlook is supported by strong analyst consensus with a $63.00 price target and 84.85% buy ratings, but risks include oil price volatility and a recent dip in profit margins. Earnings have consistently beaten expectations, providing fundamental strength amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
